LivingGLP1
parallel randomized trial

GALLOP

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies - a Pilot Study

Other conditionsNCT05920889S002078

Design

Randomized
140
Start year
2023
Treatment
1 weeks, follow-up 12.86 weeks
Countries
China (2 sites)
Sponsor
Chinese University of Hong Kong (not reported)
Eligibility
adults with ICA terminus or M1 occlusion, NIHSS 10 or more, ASPECTS 6 to 10, within 12 h, planned EVT

Conduct and analysis

Blinding
open label
Sequence generation
computer
Allocation concealment
not reported
Outcome adjudication
yes
Primary estimand
not stated
Analysis population
randomized
Missing data
worst score imputation

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Semaglutide 0.5 mg subcutaneous once weekly
Semaglutide plus reperfusion therapy
endovascular therapy with or without IV thrombolysis; lifestyle: not reported6969
A2Standard care or no added treatment
Standard therapy
endovascular therapy with or without IV thrombolysis; lifestyle: not reported7171

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticSemaglutide 0.5 mg subcutaneous once weekly
A1
Standard care or no added treatment
A2
agemean (years)69.267.2
agesd (years)10.811.1
hba1cmedian (percent)5.85.9
hba1cq1 (percent)5.55.5
hba1cq3 (percent)6.16.6
other diabetesn1017
other diabetespercent14.523.9
other malen4450
other malepercent63.870.4
sbpmean (mmHg)145.8144.3
sbpsd (mmHg)19.623.5
weightmean (kg)70.368.2
weightsd (kg)15.112.5

Results

2 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Nausea (2 lines; O27A)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
A1events3 / 69not stated; randomized; nausea/vomiting; R0002511:Table 3
A2events1 / 71not stated; randomized; nausea/vomiting; R0002511:Table 3